|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.100 USD | +4.06% |
|
+10.51% | -46.89% |
| 06-04 | Verastem Oncology Gets FDA Fast Track Designation for Lung Cancer Drug | DJ |
| 06-03 | Verastem's Lung Cancer Drug Gets FDA Fast Track Designation | MT |
| Market Cap | 360M 311M 287M 268M 503M 34.25B 511M 3.39B 1.32B 16.67B 1.35B 1.32B 57.71B | P/E Ratio 2026 * |
-2.63x | P/E Ratio 2027 * | -3.79x |
|---|---|---|---|---|---|
| Enterprise Value | 360M 311M 287M 268M 503M 34.25B 511M 3.39B 1.32B 16.67B 1.35B 1.32B 57.71B | EV / Sales 2026 * |
3.48x | EV / Sales 2027 * | 1.97x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Verastem, Inc.
| 1 day | +4.06% | ||
| 1 week | +10.51% | ||
| Current month | -5.31% | ||
| 1 month | -13.14% | ||
| 3 months | -26.79% | ||
| 6 months | -57.34% | ||
| Current year | -46.89% |
| 1 week | 3.55 |  | 4.18 |
| 1 month | 3.55 | | 4.75 |
| Current year | 3.55 | | 8.88 |
| 1 year | 3.55 | | 11.24 |
| 3 years | 2.1 | | 14.22 |
| 5 years | 2.1 | | 58.56 |
| 10 years | 2.1 | | 124.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 65 | 01/08/2023 |
Daniel Calkins
DFI | Director of Finance/CFO | 39 | 31/10/2022 |
John Hayslip
CTO | Chief Tech/Sci/R&D Officer | - | 18/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Bailey
BRD | Director/Board Member | 60 | 26/05/2026 |
Eric Rowinsky
BRD | Director/Board Member | 69 | 03/05/2017 |
John Johnson
CHM | Chairman | 68 | 15/12/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-21 | Free | Director | 36,000 | 0.0410% | ||
| 05-21 | Free | Director | 108,000 | 0.1229% | ||
| 05-21 | Free | Director | 36,000 | 0.0410% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.06% | +10.51% | -26.79% | -56.98% | 360M | |
| +1.03% | +2.30% | +55.91% | +114.22% | 56.42B | |
| +2.72% | +3.26% | +46.05% | +44.91% | 44.54B | |
| +1.12% | +2.79% | -15.04% | -21.68% | 22.9B | |
| +1.17% | +3.85% | -0.89% | +403.86% | 21.21B | |
| +3.81% | -5.07% | +11.00% | -30.62% | 16.4B | |
| +0.15% | +2.24% | +9.32% | -39.30% | 15.4B | |
| -0.69% | +0.82% | +27.75% | +176.72% | 13.35B | |
| +5.27% | +5.54% | +19.65% | - | 12.36B | |
| +1.61% | +1.28% | +95.75% | +205.26% | 11.15B | |
| Average | +2.02% | +2.93% | +22.27% | +88.49% | 21.41B | |
| Weighted average by Cap. | +1.73% | +2.38% | +31.94% | +99.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 103M 89.39M 82.37M 77.1M 144M 9.84B 147M 973M 379M 4.79B 388M 380M 16.58B | 183M 158M 145M 136M 255M 17.37B 259M 1.72B 670M 8.46B 686M 671M 29.28B |
| Net income | -164M -141M -130M -122M -229M -15.57B -232M -1.54B -600M -7.58B -615M -602M -26.23B | -137M -118M -109M -102M -191M -12.99B -194M -1.28B -501M -6.32B -513M -502M -21.89B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/26 | 4.100 $ | +4.06% | 1,600,078 |
| 11/06/26 | 3.940 $ | +4.79% | 1,534,239 |
| 10/06/26 | 3.760 $ | -1.57% | 2,221,212 |
| 09/06/26 | 3.820 $ | +4.09% | 3,069,755 |
| 08/06/26 | 3.670 $ | -1.08% | 1,866,569 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VSTM Stock
Select your edition
All financial news and data tailored to specific country editions
